CytoDyn Inc. CYDY
Set alert
0.23 USD 0.00 +2.23%
As of Nov 3, 9:37 AM ET
0.221 Day range 0.225
0.18 52-week range 0.40
- YTD
- -19.64%
- 1 year
- -13.46%
- Open
- 0.221
- Prev close
- 0.2201
- Mkt cap
- 330.64M
- Vol
- 54.60K
- Avg vol
- 1.82M
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 0.221
- High
- 0.225
- Earnings
- Jan 21, 2025
6M chart
Signals (33)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2026 | 5 days ago |
| SMA: Bullish | Oct 29, 2026 | 5 days ago |
| SMA: Bearish | Oct 28, 2026 | 6 days ago |
| MACD: Sell Signal | Oct 28, 2026 | 6 days ago |
| SMA: Bearish | Oct 27, 2026 | 1 week ago |
| RSI: Overbought | Oct 23, 2026 | 1 week ago |
| RSI: Overbought | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 2 months ago |
| SMA: Bearish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
Newest 20 of 33.
Next earnings
Jan 21, 2025
Expected Jan 21, 2025. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 21, 2025 | Nov 1, 2024 | 0.00 | — | — | — |
| Oct 15, 2024 | Aug 1, 2024 | 0.00 | 0.02 | — | — |
| Aug 15, 2024 | May 1, 2024 | 0.00 | -0.02 | — | — |
| Apr 15, 2024 | Feb 1, 2024 | 0.00 | -0.01 | — | — |
| Jan 16, 2024 | Nov 1, 2023 | 0.00 | -0.01 | — | — |
| Oct 23, 2023 | Aug 1, 2023 | 0.00 | -0.01 | — | — |
News
- CytoDyn (OTCMKTS:CYDY) Shares Break Below Two Hundred Day Moving Average – Here’s What Happened
- CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
- CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
- CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
- CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
- CytoDyn to Host Investor Webcast
- CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
- CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
- CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why
- CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
Your note
Sign in to keep a note on CYDY — it syncs with the Stock Master app.